<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81842">
  <stage>Registered</stage>
  <submitdate>14/02/2007</submitdate>
  <approvaldate>15/02/2007</approvaldate>
  <actrnumber>ACTRN12607000130460</actrnumber>
  <trial_identification>
    <studytitle>Study of a combination of fenugreek/phaseolamin as a new weight loss agent</studytitle>
    <scientifictitle>A pilot study to investigate the efficacy and tolerability of a combination of fenugreek/phaseolamin as a potential weight loss agent when given as part of a muesli bar in moderately obese patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will receive one treatment three times a day (~20min before each meal) for twelve weeks: the treatment muesli bar containing Fenulife 43 (3g/bar) and phaseolamin (0.23g/bar).</interventions>
    <comparator>Participants will receive one treatment three times a day (~20min before each meal) for twelve weeks:  the control muesli bar with no Fenulife 43 and phaseolamin.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Weight loss</outcome>
      <timepoint>At 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Weight loss</outcome>
      <timepoint>At 4 and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood hormal changes and HbA1C changes </outcome>
      <timepoint>At 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability data </outcome>
      <timepoint>At 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Overweight as defined by body mass index 30-40kg/m2Generally healthyWeight stable over previous 3 monthsWilling and able to give written informed consent.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diabetic (receiving pharmacological treatments for diabetes)Pregnant, breastfeeding, or intending to become pregnant during the studyAny medications, or medical conditions that might, in the opinion of the Principal Investigator, affect participant safety or outcomeCurrently on an alternative weight loss programme or planning to start a programme during the study durationHas a pace-makerPlanning international travel during the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be screened and enrolled on confirmation of eligibility. Randomisation to the intervention will be by computer access to a secure schedule administered by a third party process</concealment>
    <sequence>The randomisation schedule will be computer generated by a third party and accessed by staff at the time of enrolment</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The subjects and assessors will be blinded. Data entry will be blinded but data analysis will not be blinded due to the 2:1 (active:placebo) weighting.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>39</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Southern European Health Marketing Ltd</primarysponsorname>
    <primarysponsoraddress>Heritage House
235 Main Street</primarysponsoraddress>
    <primarysponsorcountry>Gibraltar</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Southern European Health Marketing Ltd</fundingname>
      <fundingaddress>Southern European Health Marketing Ltd
Heritage House
235 Main Street</fundingaddress>
      <fundingcountry>Gibraltar</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Charities/Societies/Foundations</othercollaboratortype>
      <othercollaboratorname>Medical Research Institute of New Zealand (MRINZ)</othercollaboratorname>
      <othercollaboratoraddress>PO Box 10055
The Terrace
Wellington</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>P3 Research</othercollaboratorname>
      <othercollaboratoraddress>Promed House
Suite 11
71 - 10th Avenue
Tauranga</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is looking at whether a new investigational product (a combination of fenugreek and phaseolamin in a muesli bar taken for 12 weeks) is effective at causing weight loss. Specific components in the blood are also measured to see if the product has any effect on them.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi-Region Ethics Committee</ethicname>
      <ethicaddress>The Terrace, Wellington</ethicaddress>
      <ethicapprovaldate>10/04/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Richard Beasley</name>
      <address>Medical Research Institute of New Zealand
Level 3
99 The Terrace
Wellington</address>
      <phone>+64 4 4729199</phone>
      <fax />
      <email>richard.beasley@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Richard Beasley</name>
      <address>Medical Research Institute of New Zealand
Level 3
99 The Terrace
Wellington</address>
      <phone>+64 4 472 9199</phone>
      <fax />
      <email>richard.beasley@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tanya Baker</name>
      <address>Medical Research Institute of New Zealand Level 3 99 The Terrace Wellington</address>
      <phone />
      <fax />
      <email>tanya.baker@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>